N-(1-Methyl-2-phenyl-ethyl)-hydroxylamine; hydrochloride | 4490-17-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: N-(1-Methyl-2-phenyl-ethyl)-hydroxylamine; hydrochloride
• 英文别名: hydron;N-(1-phenylpropan-2-yl)hydroxylamine;chloride
• CAS: 4490-17-9
• 化学式: C₉H₁₃NO*ClH
• 分子量: 187.669
• InChiKey: ALRZZAHTTYSVRF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.02
• 重原子数：
  12
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  32.3
• 氢给体数：
  3
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  N-(1-Methyl-2-phenyl-ethyl)-hydroxylamine; hydrochloride 在 三乙胺 、 乙腈 作用下， 以 二氯甲烷 、 乙腈 为溶剂， 反应 5.0h， 生成 N-(1-phenyl-2-propyl)-2-hydroxy-2-phenylethanamide
  参考文献：
  名称：

  Base-promoted reaction of O-sulfonylated hydroxamic acids with nucleophiles. A new method for the synthesis of .alpha.-substituted amides

  摘要：

  Treatment of a series of hydroxamic acids 2 with mesyl chloride in the presence of 2 equiv of triethylamine at 0-degrees-C gives 2-chloroamides 3 in good yields. Use of a single equivalent of triethylamine gives the (N-mesyl-oxy)amides 1, which are versatile synthetic intermediates as they can be readily converted to 2-bromoamides 4 with lithium bromide and triethylamine and to 2-hydroxyamides 5 with triethylamine in aqueous acetonitrile.

  DOI：

  10.1021/jo00047a024

文献信息

• [EN] MACROCYCLIC LACTONE COMPOUNDS AND METHODS FOR THEIR USE<br/>[FR] COMPOSÉS DE LACTONE MACROCYCLIQUES ET LEURS PROCÉDÉS D'UTILISATION
  申请人：ELIXIR MEDICAL CORP

  公开号：WO2009114010A1

  公开（公告）日：2009-09-17

  The present invention provides a pharmaceutical composition comprising a pharmaceutically acceptable excipient and a compound of the formula (I) wherein R1, R2, R3, R5, R6, R8, M1, M2, M3, M4, M5, M6 and M7 are each independently a member selected from the group consisting of H, C1-6 alkyl, OH and C1-6 hydroxyalkyl; R4, R7 and R9 are each independently selected from the group consisting of C1-6 alkoxy and OH; R10 is a member selected from the group consisting of H, -OH, -OP(O)Me2, (II), (III), -O-(CH2)n-OH and -O-(CH2)m-O-(CH2)o-CH3, wherein subscripts n and m are each independently from 2 to 8 and subscript o is from 1 to 6; each of L1 and L4 are independently selected from the group consisting of (IV) and (V) wherein each M8 is independently a member selected from the group consisting Of C1-6 alkyl, OH and C1-6 hydroxyalkyl; each of L2 and L3 are independently selected from the group consisting of (VI), (VII) and (VIII); and salts, hydrates, isomers, metabolites, N-oxides and prodrugs thereof.

  本发明提供了一种制药组合物，该组合物包括一种药用可接受的赋形剂和一种式(I)的化合物，其中R1、R2、R3、R5、R6、R8、M1、M2、M3、M4、M5、M6和M7各自独立地选择自H、C1-6烷基、OH和C1-6羟基烷基的群体中的一种；R4、R7和R9各自独立地选择自C1-6烷氧基和OH的群体中的一种；R10选择自H、-OH、-OP(O)Me2、(II)、(III)、-O-(CH2)n-OH和-O-(CH2)m-O-(CH2)o-CH3的群体中的一种，其中下标n和m各自独立地从2到8，下标o从1到6；L1和L4各自独立地选择自(VI)和(VII)的群体中的一种，其中每个M8各自独立地选择自C1-6烷基、OH和C1-6羟基烷基的群体中的一种；L2和L3各自独立地选择自(VI)、(VII)和(VIII)的群体中的一种；以及其盐、水合物、异构体、代谢物、N-氧化物和前药。
• Skin penetration system for salts of amine-functional drugs
  申请人：THE PROCTER & GAMBLE COMPANY

  公开号：EP0351897A2

  公开（公告）日：1990-01-24

  The invention involves pharmaceutical compositions for topical application comprising: (a) a pharmaceutically-acceptable salt of addition of an amine-functional drug (other than opioid analgesic drugs); (b) a C₇ to C₂₂ straight-chain or branched-chain, saturated or unsaturated, fatty acid having a melting point of less than about 50°C; and (c) a C₃-C₄ alkane diol.

  本发明涉及用于局部应用的药物组合物，包括 (a) 一种胺功能药物（阿片类镇痛药除外）的药学上可接受的加成盐； (b) C₇ 至 C₂₂ 直链或支链、饱和或不饱和脂肪酸，熔点低于约 50°C；以及 (c) C₃-C₄ 烷二醇。
• Macrocyclic lactone compounds and methods for their use
  申请人：Elixir Medical Corporation

  公开号：US10123996B2

  公开（公告）日：2018-11-13

  A pharmaceutical composition comprising a pharmaceutically acceptable excipient and a compound of the formula: wherein R1, R2, R3, R5, R6, R8, M1, M2, M3, M4, M5, M6 and M7 are each independently a member selected from the group consisting of H, C1-6 alkyl, OH and C1-6 hydroxyalkyl; R4, R7 and R9 are each independently selected from the group consisting of C1-6 alkoxy and OH; R10 is a member selected from the group consisting of H, —OH, —OP(O)Me2, —O—(CH2)n—OH and —O—(CH2)m—O—(CH2)o—CH3, wherein subscripts n and m are each independently from 2 to 8 and subscript o is from 1 to 6; each of L1 and L4 are independently selected from the group consisting of: wherein each M8 is independently a member selected from the group consisting of C1-6 alkyl, OH and C1-6 hydroxyalkyl; each of L2 and L3 are independently selected from the group consisting of: and salts, isomers, or N-oxides thereof.

  一种药物组合物，包含一种药学上可接受的赋形剂和一种式化合物： 其中 R1、R2、R3、R5、R6、R8、M1、M2、M3、M4、M5、M6 和 M7 各自独立地选自由 H、C1-6 烷基、OH 和 C1-6 羟烷基组成的组；R4、R7 和 R9 各自独立地选自由 C1-6 烷氧基和 OH 组成的组；R10 选自由 H、-OH、-OP(O)Me2 组成的组、 -O-(CH2)n-OH和-O-(CH2)m-O-(CH2)o-CH3，其中下标n和m各自独立地为2至8，下标o为1至6；L1和L4各自独立地选自由以下组成的组： 其中每个 M8 独立地是选自由 C1-6 烷基、OH 和 C1-6 羟基烷基组成的组的成员；每个 L2 和 L3 独立地是选自由以下组成的组的成员： 和 及其盐类、异构体或 N-氧化物。
• Compositions for stabilizing poly (carboxylic acids)
  申请人：——

  公开号：US20030133986A1

  公开（公告）日：2003-07-17

  Compositions and methods for reducing the decomposition rate of poly(carboxylic acids), such as hyaluronic acid. The compositions include at least one strong, stable chelating agent, preferably an organophosphorous compound such as diethylene triamine penta(methylene phosphonic acid). These biocompatible compositions are especially useful in the ophthalmic field. Also disclosed is a method of performing surgery on an eye including employing a hyaluronic acid material utilizing the inventive composition of the present invention.

  降低透明质酸等聚羧酸分解率的组合物和方法。这些组合物至少包括一种强力、稳定的螯合剂，最好是一种有机磷化合物，如二亚乙基三胺五亚甲基膦酸。这些生物相容性组合物在眼科领域特别有用。本发明还公开了一种对眼睛进行手术的方法，包括利用本发明组合物的透明质酸材料。
• EP1027015A4
  申请人：——

  公开号：EP1027015A4

  公开（公告）日：2001-06-27